Japan Chemical Research Licenses Erythropoietin Rights To GSK
This article was originally published in PharmAsia News
Executive Summary
Japan Chemical Research announced Dec. 18 a licensing agreement with GlaxoSmithKline that grants GSK exclusive rights to develop and market recombinant erythropoietin for chronic renal anemia outside Japan